Search

Perfluorohexyloctane

[A259741] It was approved by the FDA on May 18, 2023 for the treatment of dry eye disease.[L46536] … [A259746, A259751] Perfluorohexyloctane has been used in the field of ophthalmology as a vitreous substitute.

Human C1-esterase inhibitor

of the immune system. … The primary function of endogenous C1INH is to regulate the activation of the complement and contact system pathways.

Pyrophosphoric acid

Dinutuximab

It is composed of the variable heavy- and light-chain regions of the murine anti-GD2 mAb 14.18 and the constant regions of human IgG1 heavy-chain and kappa light-chain. … restricted expression on normal tissues.

Ecabet

Ecabet represents a new class of molecules that increases the quantity and quality of mucin produced by conjunctival goblet cells and corneal epithelia. … Ecabet is a prescription eye drop for the treatment of dry eye syndrome.

Finerenone

[A236544,L34739] Finerenone was granted FDA approval on 9 July 2021,[L34739] followed by the EMA approval on 11 March 2022.[L41449] … Finerenone, or BAY 94-8862, is a mineralocorticoid receptor antagonist indicated to reduce the risk of sustained decline in glomerular filtration rate, end stage kidney disease, cardiovascular death, heart

Angiotensin II

in adults with septic or other distributive shock. … Shock is the inability to maintain blood flow to vital tissues and the potential resultant organ failure and death within hours, no matter young or o ld.

Sonidegib

It was FDA approved in 2015 for the treatment of basal cell carcinoma.

Galcanezumab

[A33112] Galcanezumab was approved by the FDA in September 2018, and is indicated for the preventive treatment of migraine and the treatment of episodic cluster headache. … [L42060] It is unknown if galcanezumab has an effect on pregnancy outcomes. A pregnancy exposure registry has been established to evaluate the safety of this drug in pregnant women.[L42060]

Macimorelin

Risk factors of AGHD include a history of childhood-onset GH deficiency or with hypothalamic/pituitary disease, surgery, or irradiation to these areas, head trauma, or evidence of other pituitary hormone … and diagnosis of AGHD.